How Does Untreated OSA Impact Chronic Comorbid Conditions and Healthcare Costs?

Join Chris Fernandez, EnsoData Co-Founder and CEO, for a summary of research examining the economic impact of Obstructive Sleep Apnea (OSA) therapy compliance, including:
  • Prevalence of undiagnosed OSA
  • Rate of diagnosed patients not starting continuous positive airway pressure (CPAP) therapy
  • Spectrum of CPAP treatment adherence
  • Effects of concurrent co-morbidities on patient health
After the presentation, the following research contributors join Chris for a Q&A session moderated by research co-author, Mark Kaiser, EnsoData VP of Business and Partnership Development:
  • Ian Duncan, PhD, FSA, MAAA, Adjunct Professor of Actuarial Statistics, University of California Santa Barbara, President, Santa Barbara Actuaries Inc.
  • Nathaniel F. Watson, MD, MSc, Adjunct Professor, Department of Neurological Surgery, University of Washington (UW) School of Medicine, Principal, NeuroSleep LLC
  • Jen McClurg, MBA, SVP Payor Solutions, EnsoData
Simply fill out our form to watch the webinar on-demand.

Watch Now

"*" indicates required fields